Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by bossofthemosson Jul 28, 2006 3:43pm

422 Views

Post# 11160461

RE: ROB TV

I hope I'm wrong but Lawgix and a few other posters have got to see an optometrist for those rose-colored glasses. The market does not lie and it is telling us that management's integrity has been in question for a long time now and it is going to take something very special for that to change. I don't see it coming. Thank goodness RVX represents only a fraction of my portfolio unlike most of the posters here.

Bullboard Posts

Pro Women’s Hockey League comes to NHL 25 in December